MG
CMPX icon

Michael Gelband’s Compass Therapeutics CMPX Stock Holding History

Michael Gelband’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
67,478
+23,448
+53% +$69.2K ﹤0.01% 1445
2026
Q1 		$233K Buy
+44,030
New +$254K ﹤0.01% 1359
2023
Q2 		– Sell
-16,840
Closed -$55K – 1897
2023
Q1 		$55K Buy
+16,840
New +$66.1K ﹤0.01% 1657

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's CMPX Position: Q2 2026 in Review

Michael Gelband increased its Compass Therapeutics (CMPX) stake by 53% in Q2 2026, buying an estimated $69.2K and bringing the position to 67,478 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

Michael Gelband first reported a position in CMPX in Q1 2023 and has held it in 3 quarters since. The position peaked at $233K in Q1 2026. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Michael Gelband held 67,478 shares of Compass Therapeutics worth $148K as of Q2 2026.
  • Michael Gelband bought 23,448 Compass Therapeutics shares in Q2 2026, an estimated $69.2K.
  • Compass Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1445 holding.
  • Michael Gelband first reported a position in Compass Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Michael Gelband's Compass Therapeutics position peaked at $233K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.